Key facts
- It has raised $9.0M; the latest was Merger/Acquisition in Jan 2026.
- Status: Acquired/Merged.
- ·Watchlist + deal alerts for Terrain Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Terrain Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Terrain Bio
Developer of computational and laboratory services designed for the design and production of biological molecules for research and development purposes. The company's platform combines algorithmic sequence design, multi-parameter evaluation of molecular features, iterative optimization using experimental feedback, and integrated production workflows supporting small to moderate batch outputs, enabling biotechnology and pharmaceutical research teams to generate, test, and refine RNA-based constructs more efficiently, consistently, and reproducibly across early discovery and preclinical development activities.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2023
- Employees
- 19
- Website
- terrain.bio/
- Ownership
- Acquired/Merged
Terrain Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Terrain Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Terrain Bio in its N-PORT filings yet. We sweep new filings monthly.